HOLX Stock Overview
Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.81 |
| 52 Week High | US$82.45 |
| 52 Week Low | US$64.02 |
| Beta | 1.01 |
| 1 Month Change | -1.85% |
| 3 Month Change | -1.41% |
| 1 Year Change | -6.04% |
| 3 Year Change | 19.20% |
| 5 Year Change | 71.62% |
| Change since IPO | 3,029.31% |
Recent News & Updates
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
May 22
Hologic: Women's Health Play Looks Healthier Itself
May 13Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult
Apr 19Recent updates
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
May 22Hologic: Women's Health Play Looks Healthier Itself
May 13Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult
Apr 19Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)
Apr 05Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet
Mar 20Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching
Feb 22Hologic: Prospects For Growth As Headwinds Disappear
Feb 11We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings
Feb 09Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next
Feb 06We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)
Jan 29The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)
Dec 30Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?
Dec 11We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt
Nov 08Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?
Oct 25Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement
Sep 28Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price
Aug 29We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt
Jul 31Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching
Jul 18Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing
Jun 21Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)
May 22We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt
Apr 25What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?
Apr 10Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher
Mar 13Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)
Feb 14Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly
Jan 18Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?
Jan 03Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns
Dec 02Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly
Oct 12Is Hologic, Inc. (NASDAQ:HOLX) Potentially Undervalued?
Sep 27Hologic announces $1B share buyback program
Sep 26We Like Hologic's (NASDAQ:HOLX) Returns And Here's How They're Trending
Aug 27Shareholder Returns
| HOLX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.07% | -0.2% | -0.2% |
| 1Y | -6.0% | 5.2% | 28.2% |
Return vs Industry: HOLX underperformed the US Medical Equipment industry which returned 4.2% over the past year.
Return vs Market: HOLX underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| HOLX volatility | |
|---|---|
| HOLX Average Weekly Movement | 2.3% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HOLX has not had significant price volatility in the past 3 months.
Volatility Over Time: HOLX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HOLX fundamental statistics | |
|---|---|
| Market cap | US$17.40b |
| Earnings (TTM) | US$466.50m |
| Revenue (TTM) | US$3.96b |
37.4x
P/E Ratio4.4x
P/S RatioIs HOLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOLX income statement (TTM) | |
|---|---|
| Revenue | US$3.96b |
| Cost of Revenue | US$1.56b |
| Gross Profit | US$2.40b |
| Other Expenses | US$1.93b |
| Earnings | US$466.50m |
Last Reported Earnings
Mar 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.00 |
| Gross Margin | 60.50% |
| Net Profit Margin | 11.78% |
| Debt/Equity Ratio | 52.7% |
How did HOLX perform over the long term?
See historical performance and comparison